Reduced dose OKT3 prophylaxis in sensitised kidney recipients

Area of Science:

• Nephrology
• Immunology
• Transplant Surgery

Background:

• Sensitized renal transplant recipients face a high risk of organ rejection.
• Prophylactic immunosuppression is crucial for preventing rejection in these vulnerable patients.
• The monoclonal antibody OKT3 is a key agent in preventing transplant rejection.

Purpose of the Study:

• To evaluate the efficacy and safety of a reduced-dose regimen of OKT3 for preventing rejection in sensitized renal transplant recipients.
• To compare the outcomes of a reduced-dose (RD) regimen with a standard full-dose (FD) regimen of OKT3.
• To assess the cost-effectiveness of the RD OKT3 regimen.

Main Methods:

• A comparative study of two groups of sensitized renal transplant recipients.
• Group 1 received a full dose (FD) regimen of OKT3.
• Group 2 received a reduced dose (RD) regimen of OKT3, with similar patient demographics and pre-transplant characteristics.

Main Results:

• Both FD and RD OKT3 regimens demonstrated excellent patient and graft survival rates at 12 months (FD: 8/8 patients, 7/8 grafts; RD: 17/17 patients, 17/17 grafts).
• Creatinine levels at 24 months were comparable between the groups (FD: 185 +/- 68 mumol/l; RD: 201 +/- 81 mumol/l).
• The RD regimen reduced the cost per patient by 40% compared to the FD regimen.

Conclusions:

• A reduced-dose regimen of OKT3 is as effective as the standard full-dose regimen in preventing rejection in sensitized renal transplant recipients.
• The RD OKT3 regimen offers comparable clinical outcomes with significant cost savings.
• This study supports the use of a reduced-dose OKT3 strategy for improved economic efficiency in renal transplantation.